
Opinion|Videos|June 24, 2024
Key Updates from ARMANI in Advanced HER2- Gastric/GEJ Cancer
Mark A. Lewis, MD, and the Oncology Brothers discuss recent updates from the ARMANI trial in HER2- gastric/ gastroesophageal junction cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































